华蟾素抗恶性肿瘤的研究进展简

华蟾素为我国自行研制和开发的二类新药,具有增强机体免疫力、抑制肿瘤细胞增殖、镇痛等药理作用,可提高中晚期癌症患者的生活质量,延长生存期,在临床治疗中应用广泛.华蟾素对恶性肿瘤的临床疗效已得到初步认可,运用现代科学技术,进一步深入研究其药理作用机制,充分发挥其独特疗效,更好地指导临床用药,仍是今后进一步研究的方向.随着华蟾素在临床抗肿瘤中的广泛应用,现就华蟾素抗恶性肿瘤的机制、毒副作用及临床应用的研究进展做一综述.

Research progress on anti-tumor of cinobufagin

As a kind of second-class and self-developed new drug, cinobufagin can improve body immunity function, inhibit tumor cell proliferation, ease pain and so on. It can improve the quality of middle-late phased cancer patients＂ life, prolong their survival time. It has been widely used in clinical treatment. Cinobufagin＇s clinical effect on malig- nant tumor has been already admitted provisionally. It remains the direction of research in the future, that using mod- ern science and technology to further study its pharmacological mechanisms, fully play it＇s unique efficacy and guide clinical medication more reasonably. As einobufagin has＇ been widely used in clinical anti-tumor, this paper summa- rizes the research progress of cinobufagin＇s anti-tumor, mechanism, adverse reaction, and clinical application.